Acorda Therapeutics to Present at Leerink Swann Global Healthcare Conference

  Acorda Therapeutics to Present at Leerink Swann Global Healthcare Conference

Business Wire

ARDSLEY, N.Y. -- February 7, 2013

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Jane Wasman,
President, International and General Counsel will present at the Leerink Swann
Global Healthcare Conference on Thursday, February 14 at 9:00 am ET at The
Waldorf=Astoria Hotel in New York.

A live audio webcast of the presentation can be accessed under “Investor
Events” in the Investor section of the Acorda website at www.acorda.com, or
you may use the link:

http://leerink.metameetings.com/webcasts/healthcare13/directlink?p=5

Please log in approximately 5 minutes before the scheduled time of the
presentation to ensure a timely connection. An archived version of the webcast
will be available until March 14, 2013 on the Investors section of
www.acorda.com.

About Acorda Therapeutics

Acorda Therapeutics is a biotechnology company focused on developing therapies
that restore function and improve the lives of people with MS, spinal cord
injury and other neurological conditions.

Acorda markets AMPYRA^® (dalfampridine) Extended Release Tablets, 10 mg, in
the United States as a treatment to improve walking in patients with multiple
sclerosis (MS). This was demonstrated by an improvement in walking speed.
AMPYRA is marketed outside the United States as FAMPYRA^® (prolonged-release
fampridine tablets) by Biogen Idec under a licensing agreement from Acorda.
AMPYRA and FAMPYRA are manufactured under license from Alkermes Pharma Ireland
Limited.

The Company also markets ZANAFLEX CAPSULES^® (tizanidine hydrochloride) and
Zanaflex tablets, a short-acting drug for the management of spasticity. Acorda
also receives sales royalties on tizanidine hydrochloride capsules, an
authorized generic version of ZANAFLEX CAPSULES distributed by Watson
Pharmaceutics, Inc. under its agreement with Acorda.

Acorda has an industry-leading pipeline of novel neurological therapies. The
Company is developing Diazepam Nasal Spray for treatment of certain epileptic
seizures. It is also studying AMPYRA to improve a range of functional
impairments caused by MS, as well as its potential for use in other
neurological conditions, including cerebral palsy and post-stroke deficits. In
addition, Acorda is developing clinical stage compounds AC105 for acute
treatment of spinal cord injury, GGF2 for treatment of heart failure and
rHIgM22, a remyelinating monoclonal antibody, for the treatment of MS.GGF2 is
also being investigated in preclinical studies as a treatment for neurological
conditions such as stroke and spinal cord injury. Chondroitinase, an enzyme
that encourages nerve plasticity in spinal cord injury, is in preclinical
development.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. All statements, other
than statements of historical facts, regarding management's expectations,
beliefs, goals, plans or prospects should be considered forward-looking. These
statements are subject to risks and uncertainties that could cause actual
results to differ materially, including our ability to successfully market and
sell Ampyra in the U.S.; third party payers (including governmental agencies)
may not reimburse for the use of Ampyra or our other products at acceptable
rates or at all and may impose restrictive prior authorization requirements
that limit or block prescriptions; the risk of unfavorable results from future
studies of Ampyra or from our other research and development programs,
including Diazepam Nasal Spray (“DZNS”) or any other acquired or in-licensed
programs; we may not be able to complete development of, obtain regulatory
approval for, or successfully market DZNS or other products under development;
the occurrence of adverse safety events with our products; delays in obtaining
or failure to obtain regulatory approval of or to successfully market Fampyra
outside of the U.S. and our dependence on our collaboration partnerBiogen
Idecin connection therewith; competition, including the impact of generic
competition on Zanaflex Capsules revenues; failure to protect our intellectual
property, to defend against the intellectual property claims of others or to
obtain third party intellectual property licenses needed for the
commercialization of our products; failure to comply with regulatory
requirements could result in adverse action by regulatory agencies; and the
ability to obtain additional financing to support our operations. These and
other risks are described in greater detail inAcorda Therapeutics'filings
with the Securities & Exchange Commission.Acordamay not actually achieve the
goals or plans described in its forward-looking statements, and investors
should not place undue reliance on these statements. Forward-looking
statements made in this release are made only as of the date hereof, and
Acorda disclaims any intent or obligation to update any forward-looking
statements as a result of developments occurring after the date of this
release.

Contact:

Acorda Therapeutics
Jeff Macdonald, 914-326-5232
jmacdonald@acorda.com
 
Press spacebar to pause and continue. Press esc to stop.